Navigation Links
hemoCARE Guaiac FOB test

ProductshemoCARE Guaiac FOB test
Company CARE Products diagnostica
Item hemoCARE Guaiac FOB test
Features 
  • Three boxes per slide are used for the application of stool specimens.
  • The buffered developer solution provides a stable pH-value, which results in optimal color development for the test's interpretation.
  • hemoCARE's high quality filter paper allows the blue colors flow to the periphery in positive tests making it easier to read.
Description Worldwide, approximately 500,000 people die each year of colon cancer - including 57,000 Americans. Despite diagnostic improvements (high contrast berium enema, colonoscopy, FOBT, flexible sigmoidoscopy, etc.) an increase in the success rate of curative treatment for colorectal carcinomas has not been achieved over the past two decades. The chances of successful treatment are essentially dependent on the stage of the tumor's development and the beginning of treatment. In stage I, the success rate is approximately 96%. Unfortunately, symptoms are minimal in the early stages of the development of a tumor or neoplastic polyps. As a result, treatment usually begins at an advanced stage.
Info CARE Products diagnostica
Customer Service: 866.332.5850
Web site: http://www.careproductsonline.com

Related medicine products :

1. Hemaprompt Fecal Occult Blood Test
2. Gastroccult Gastric Occult and pH Test
3. TAB™ Thermocouple Esophageal Stethoscopes with Temperature Sensor-GS (Gastric Suction)
4. 400 Series Thermistor Esophageal Stethoscopes with Temperature Sensor-GS (Gastric Suction)
5. Gastric Analysis
6. Gastric Brush/Wash for Cytology
7. Gastric Inhibitory Polypeptide
8. Occult Blood, Gastric
9. Hemoccult Fecal Occult Blood Test
10. Hemoccult II SENSA elite Fecal Occult Blood Test
11. Hemoccult SENSA Fecal Occult Blood Test
... The Mayfield 2000 series radiolucent headrest system ... intraoperative digital subtraction angiography. This system is ... skull clamp and the Mayfield radiolucent base ... designed for patient positioning in the prone ...
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Hudson hand drill with extension piece....
Sighting and visualization system of the digital operating suite. The platform that links navigation, and intra-operative imaging to form the ultimate surgical workstation....
Medicine Products:
(Date:12/6/2009)... NEW ORLEANS, Dec. 6 Onyx Pharmaceuticals, ... safety data from the pivotal Phase 2b 003-A1 ... carfilzomib is well-tolerated in heavily pre-treated relapsed and ... today at the ASH/ASCO Joint Symposium at the ... Hematology (ASH) in New Orleans. Enrollment in this ...
(Date:12/6/2009)... the community, in cooperation with the Greater VA Healthcare System in ... year,s attendance is expected to soar to more than 5,000 veterans, ... ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of ... West Los Angeles, will once again create a holiday party. This ...
(Date:12/5/2009)... December 5 The first Football,for Hope Centre ... opened its doors,today (5 December 2009). FIFA President ... Helen Zille, 2010 FIFA World Cup Organising Committee,South ... Association,President Kirsten Nematandani and Executive Mayor of the ...
(Date:12/5/2009)... advanced Technology Center helps companies develop and test their cleaning processes. ... a variety of industries and solve problems for customers relating to ... ... December 5, 2009 -- Midbrook, Inc , a Jackson, MI-based ...
(Date:12/4/2009)... NEW YORK, Dec. 4 Care Investment Trust Inc. ... that its Board of Directors has declared a dividend of $0.17 ... December 22, 2009 to common shareholders of record on December 14, ... ,, Care Investment Trust Inc. is a real estate investment and ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... 15 The Houston Chapter of the American,Association ... with a donation of $35,000 to advance cancer ... Neuroblastoma Research Program led by surgeon,Eugene Kim. The ... to,block blood vessel growth in neuroblastoma, a deadly ...
... play role in immune, inflammatory processes, study says ... psoriasis have higher levels of the obesity-related hormone leptin ... Taiwanese study included 77 psoriasis patients and a control ... The researchers gathered health information about the participants and ...
... The board of directors of,Eli Lilly and Company (NYSE: ... in,its quarterly dividend. The board declared a dividend for ... common stock. This raises the,annual indicated rate to $1.96 ... company has increased the dividend payment. , ...
... Children & High School Student Volunteers Collaborate in Musical ... N.J. and HAWTHORNE, N.J., Dec. 15 ... performing arts organization and conservatory bringing together individuals with ... is pleased to announce that its members, all children ...
... are "addicted" to a family of proteins produced by ... halts cell proliferation in the deadliest cancer of the ... of California, Berkeley scientists at the American Society for ... in San Francisco. , In 30-60 percent of human ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today provided the ... , The Food and Drug Administration (FDA) ... The new draft guidance is open for public comment, ... generic applicants beyond the in vitro dissolution testing ...
Other Medicine News:Health News:Drilling Engineers Donate $35,000 to Texas Children's Hospital 2Health News:Obesity-Related Hormone Tied to Psoriasis 2Health News:Sharing The Arts & Ridgewood High School Present Musical Production of Charlie and The Chocolate Factory 2Health News:Stopping ovarian cancer by blocking proteins coded by notorious gene 2Health News:ViroPharma Provides Update on Vancocin(R) 2Health News:ViroPharma Provides Update on Vancocin(R) 3Health News:ViroPharma Provides Update on Vancocin(R) 4
(Date:12/4/2009)... Hospira, Inc. (NYSE: HSP ), a leading ... the launch of its next-generation 50 mL and 100 ... and now offers a complete size range (50 mL ... product. The launch of the 50 mL and 100 ...
(Date:12/4/2009)... Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today ... study demonstrating the effectiveness of Valortim® in an ... (NZW) rabbit. The data are being presented ...
(Date:12/4/2009)... 4 Axsun Technologies, Inc., a wholly-owned subsidiary of ... initial development and successful testing of a novel integrated ... this proprietary optical engine design raises the bar on ... for swept source OCT light sources. This approach ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Abbott Hosts Conference Call for Third Quarter Earnings 14252 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 1Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 2Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 3Oncolytics Biotech 28R 29 Inc Announces Start of Enrolment in U S Phase 2 Melanoma Cancer Clinical Trial 5057 4Babies see it coming 58252 1Babies see it coming 58252 2